Clinical and prognostic value of elevated CA125 levels in patients with coronary heart disease

Rong, Xia-Jun; Yunke, Z; Li, Guoping; Zhenyue, C.

doi:10.1007/s00059-014-4109-y

Cited by 11 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased CA-125 levels have been reported in different cardiac pathologies including CHF, coronary heart disease (CHD), AF and valve disease such as aortic stenosis and mitral stenosis. 5 - 7 , 11 , 12 Although there are few reports, the increased CA-125 levels is also documented in AMI. 7 - 9 …”

Section: Discussionmentioning

confidence: 99%

“…The role of hemodynamic abnormalities and inflammatory cytokines on the CA-125 levels have been recommended in malignant, non-malignant and chronic diseases like CHF. 3 - 7 These may also have a role in the development of atherosclerosis and its complications. 14 Mechanical stress and inflammation could induce CA-125 synthesis from the mesothelial cells of the peritoneum, pleura, and pericardium.…”

Section: Discussionmentioning

confidence: 99%

“…Although myocardial production of CA-125 have not been documented, the possibility could not be excluded. Rong and colleagues 7 have suggested that ischemic injury of myocardium causing possible ventricular remodeling and heart enlargement would have a role in the secretion of CA125 in CHD patients. However, these findings need more investigations.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, various studies have reported prognostic role of increased CA-125 in different cardiac diseases. 4 - 7 Increased levels of CA-125 are also shown in patients with acute coronary syndrome and systolic dysfunction or acute heart failure. 8 …”

Section: Introductionmentioning

confidence: 99%

“…There are few previous studies reporting increased CA-125 levels in patients with MI. 7 - 9 In this study, we measured CA-125 levels in patients with acute MI and its prognostic role in evaluating the outcome of MI.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

Separham

Abbasnezhad

Shahnazarli

et al. 2018

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

Introduction: Cancer antigen 125 (CA-125) is a tumor marker of ovarian cancer, which has shown to be increased in different cardiovascular diseases. Although the prognostic role of CA-125 in heart failure and coronary heart disease is well-established, there is little known about its role in acute myocardial infarction (AMI). In this study we aimed to evaluate the serum levels of CA-125 in patients with AMI and its prognostic role in evaluating the in-hospital outcome of AMI. Methods: We evaluated 120 male patients with AMI and 120 male normal subjects. CA-125 levels were measured upon the patient’s admission to hospital. The in-hospital major adverse cardiac events (MACE) and its predictors were also recorded for AMI patients. Results: CA-125 levels were significantly higher in AMI patients compared to normal subjects (7.99±6.83 vs. 5.70±4.62, P = 0.003). We found significant positive correlations between CA-125 levels with creatine kinase-MB (CKMB) (r=0.621, P < 0.001) and CTnI (r=0.491, P < 0.001). The in-hospital MACE was observed in 19 cases (15.8%). Patients with MACE had significantly higher value of CA-125, CKMB and CTnI and lower LVEF compared to patients without MACE. CKMB (OR=0.967, 95% CI [0.943-0.991], P = 0.007) and CA-125 levels (OR=0.821, 95% CI [0.688-0.979], P = 0.02) were independent predictors of MACE. Conclusion: Serum CA-125 levels are significantly higher in male patients with AMI compared to normal subjects and have a significant role in predicting in-hospital MACE after AMI. In patients with higher CA-125 more aggressive treatment and close observation should be performed in order to reduce the possible adverse outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

Separham

Abbasnezhad

Shahnazarli

et al. 2018

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

show abstract

The role of carbohydrate antigen 125 in COVID-19

Dökümcü¹

2021

Medical Hypotheses

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is an inflammatory process with complex pathophysiology and by affecting the cardiovascular system directly or indirectly that causes life threatening cardiac injuries. Therefore, clarifying the effects of this infection on the cardiovascular system is of importance in terms of the clinical course of the disease. The increases in cardiac and inflammatory biomarkers in COVID-19 have been associated with poor prognosis and mortality. However, there are no specific laboratory markers yet to assess the severity of the disease. In this context, the combination of available biomarkers is needed to better define the clinical course of this disease. Carbohydrate antigen 125 (CA-125) has become a remarkable marker in recent years as a result of the correlation of increasing levels in cardiovascular diseases with clinical, hemodynamic, echocardiographic parameters and its relation with mortality or re-hospitalization due to heart failure. These findings suggest that CA-125 might be useful biomarker to identify the damage mechanisms of COVID-19, monitoring the prognosis of the disease and the course of the treatment.

show abstract

Carbohydrate antigen 125 for mortality risk prediction following acute myocardial infarction

Falcão

Oliveira²,

Cantarelli³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Carbohydrate antigen 125 (CA125) is a congestion and inflammation biomarker and has been proved to be related to a worse prognosis in heart diseases. However, the precise relationship between elevated CA125 in patients with ST-segment elevation myocardial infarction (STEMI) has not yet been sufficiently studied. We set out to determine the association of CA125 with all-cause mortality at 6 months in STEMI. CA125, N-terminal pro brain natriuretic peptide (NTproBNP) and high sensitive C-reactive protein (hs-CRP) were measured in 245 patients admitted consecutively with STEMI undergoing coronary angioplasty. The mean age in our sample was 63.7 years, 64.9% were males, 28.3% had diabetes and 17.7% presented with acute heart failure (Killip ≥ 2). The median serum level of CA125 was 8.1 U/ml. At 6 months, the rate of all-cause mortality was 18% (44 patients). Receiver operating characteristic curve analysis demonstrated that CA125 presented similar performance to predict mortality as NTproBNP and hs-CRP. Patients with CA125 ≥ 11.48 had a higher rate of mortality (Hazard Ratio = 2.07, 95% confidence interval = 1.13-3.77, p = 0.017) than patients with CA125 < 11.48. This study suggests that elevated CA125 levels might be used to identify patients with STEMI with a higher risk of death at 6 months. CA125 seems to be a similar predictor of mortality compared to NTproBNP and hs-CRP. Myocardial infarction with ST-segment elevation (STEMI) is a life-threatening disorder with high morbidity and mortality despite advances in treatment. Patients presenting with STEMI tend to be heterogeneous and immediate risk stratification at the time of presentation is essential for optimal management 1-4. Markers of congestion and inflammation, such as natriuretic peptides (NP) and high sensitive C-reactive protein (hs-CRP), have been shown to be prognostic markers. However, the biomarkers currently available are not perfect, and their correct interpretation requires careful consideration of the specific clinical scenario 5. Carbohydrate antigen 125 (CA125) is a congestion and inflammation biomarker. It has been studied in patients with heart diseases, especially heart failure 6. However, the precise relationship between elevated CA125 in patients with STEMI and cardiovascular events has not yet been sufficiently studied. This study set out to evaluate the relationship between CA125 and mortality in STEMI patients in comparison with N-Terminal pro brain natriuretic peptide (NTproBNP) and hs-CRP. Methods patients and study design. This was a prospective cohort at a single center. Patients consecutively admitted with STEMI undergoing primary angioplasty were included. The diagnosis of STEMI was made based on the third universal definition 7. Two hundred and seventy one patients were considered to be included. Patients were excluded if they had chronic heart failure (n = 3), previous coronary revascularization (n = 11), kidney failure (n = 8), absence of severe coronary disease (n = 4), end-stage liver disease, ongoing infection or malignancy.

show abstract

Clinical and prognostic value of elevated CA125 levels in patients with coronary heart disease

Abstract: The serum CA125 levels were significantly related with cardiac function in CHD patients. Serum CA125 levels that remain elevated after CHD onset could be helpful for predicting the short-term risk of heart failure events in CHD patients.

Cited by 11 publications

References 17 publications

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

The role of carbohydrate antigen 125 in COVID-19

Carbohydrate antigen 125 for mortality risk prediction following acute myocardial infarction

Contact Info

Product

Resources

About